SNN - Smith & Nephew plc

NYSE - NYSE Delayed Price. Currency in USD

Smith & Nephew plc

15 Adam Street
London WC2N 6LA
United Kingdom
44 20 7401 7646
http://www.smith-nephew.com

SectorHealthcare
IndustryMedical Devices
Full Time Employees15,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Graham Timothy BakerCFO & Exec. Director1.78MN/A1968
Mr. Namal NawanaCEO & Exec. DirectorN/AN/A1971
Mr. Mark GladwellPres of Global OperationsN/AN/A1975
Ms. Catheryn O'RourkeChief Legal & Compliance OfficerN/AN/A1973
Mr. Joe MetzgerSr. VP of Marketing Services & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

Corporate Governance

Smith & Nephew plc’s ISS Governance QualityScore as of November 1, 2018 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.